NCT06070116View on ClinicalTrials.gov

Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

April 5, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2026

Conditions
Onchocercal Subcutaneous NoduleOnchocerciasisOnchocerciasis, OcularOnchocerca InfectionTropical Disease
Interventions
DRUG

Ivermectin w/ Albendazole

Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg) plus Albendazole (ALB) (400 mg)

DRUG

Ivermectin + Diethylcarbamazine + Albendazole

Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg), Diethylcarbamazine (DEC) (6 mg/kg) and Albendazole (ALB) (400 mg)

DRUG

Moxidectin + Albendazole

Participants will be given a dose of oral Moxidectin (Mox) (8 mg) plus Albendazole (ALB) (400 mg)

DRUG

Moxidectin + Diethylcarbamazine + Albendazole

Participants will be given a dose of oral Moxidectin (Mox) (8 mg), Diethylcarbamazine (DEC) (6 mg/kg) and Albendazole (ALB) (400 mg)

Trial Locations (1)

Unknown

Bong County Hospital, Bong Town

All Listed Sponsors
collaborator

National Public Health Institute of Liberia

UNKNOWN

lead

Washington University School of Medicine

OTHER